The University of Cambridge Department of Pathology and the AstraZeneca Discovery Centre in Cambridge invite applications for a 4-year PhD studentship starting 1 October 2027. The project is jointly supervised by Prof.
Andrew Firth and Dr Giovanni Ciotta, spanning both sites to enable cross-institution collaboration on peptide-bond skipping for protein engineering. The project will explore 2A sequences, ribosome skipping, and their biotechnological applications, with opportunities to learn
#J-18808-Ljbffr
PhD in Protein Engineering: 2A Peptides & Ribosome Skipping in Cambridge employer: ASTRAZENECA UK LIMITED
AstraZeneca UK Limited is an exceptional employer, offering a dynamic work environment in Luton that fosters innovation and collaboration. With a strong commitment to sustainability and employee development, you will have access to unique growth opportunities and the chance to make a meaningful impact on global initiatives. Join a diverse team where your expertise in ESG strategy and SAP will be valued and where you can contribute to transformative projects that shape the future of healthcare.
